Endo has acquired Indevus through a tender offer and subsequent merger upon which Indevus became a wholly owned subsidiary of Endo.
The common stock of Indevus ceased trading at market close on March 23, 2009 and has been converted into the right to receive $4.50 per Indevus share in cash and up to an additional $3 per share in cash upon achievement of certain regulatory and sales milestones.